SEB Asset Management’s Travere Therapeutics TVTX Stock Holding History

SEB Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.36M	Buy	+164,673	New	+$7.3M	0.04%	350

Other funds holding TVTX

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PIP

Palisades Investment Partners Santa Monica, California $352M AUM 76.79% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SEB Asset Management's TVTX Position: Q2 2026 in Review

SEB Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 164,673 shares worth $9.36M. The stake represents 0.04% of the portfolio and ranks #350 among its holdings.

71 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

SEB Asset Management held 164,673 shares of Travere Therapeutics worth $9.36M as of Q2 2026.
Travere Therapeutics was a new SEB Asset Management position in Q2 2026.
Travere Therapeutics made up 0.04% of SEB Asset Management's portfolio in Q2 2026, its #350 holding.
71 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.